Perrigo Appoints Interim CEO Following Resignation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Leadership Change: Perrigo's Board has appointed Albert A. Manzone as Interim CEO following the resignation of Patrick Lockwood-Taylor due to personal conduct issues, highlighting the company's commitment to leadership standards.
- Strategic Continuity: As Interim CEO, Manzone pledges to maintain the company's strategic direction and momentum in value creation, reflecting confidence in the company's future despite leadership changes.
- Reaffirmed Performance Outlook: Perrigo has reaffirmed its 2026 financial outlook, projecting net sales growth between -5.5% and -1.5%, indicating stability in financial expectations amid leadership transitions.
- Extensive Leadership Experience: With over 30 years of global leadership experience across various industries, Manzone is expected to bring fresh perspectives and opportunities for value creation to Perrigo.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 11.170
Low
18.00
Averages
20.33
High
23.00
Current: 11.170
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perrigo Appoints New CEO to Maintain 2026 Outlook
- Executive Change: Perrigo has appointed Albert A. Manzone as interim president and CEO effective immediately, following the resignation of former CEO Patrick Lockwood-Taylor, indicating a swift leadership adjustment to address market challenges.
- Leadership Experience: Manzone has served on Perrigo's Board since 2022 and brings over 30 years of global leadership experience, providing essential strategic guidance and stability during the company's transition period.
- Financial Outlook Maintained: Perrigo reaffirms its 2026 financial outlook, projecting adjusted EPS between $2.00 and $2.30, and core adjusted EPS between $2.25 and $2.55, demonstrating the company's confidence in its future performance.
- Cost Savings Target: The company also reiterated its sales growth targets while aiming for $60 million to $80 million in cost savings, which will enhance profitability and support long-term growth strategies.
See More
Albert A. Manzone Appointed Interim CEO Following Lockwood-Taylor's Resignation
- Leadership Transition: Perrigo Company has appointed Albert A. Manzone as Interim CEO effective immediately following Patrick Lockwood-Taylor's resignation due to personal conduct deemed inconsistent with the company's values, although this conduct did not affect business operations or financial reporting.
- Board Confidence: The Board expresses full confidence in Manzone's leadership capabilities, citing his 30 years of global experience and business transformation expertise as critical for maintaining strategic stability during this transition and continuing value creation.
- 2026 Outlook Reaffirmed: Perrigo reaffirmed its 2026 financial outlook, projecting net sales growth between -5.5% and -1.5%, and adjusted EPS of $2.00 to $2.30, indicating clarity in financial goals despite the leadership change.
- Manzone's Priorities: As Interim CEO, Manzone emphasizes continuity of the company's strategy and support for the leadership team to sustain momentum in value creation, demonstrating his commitment to the company's future growth.
See More
Perrigo Appoints Interim CEO Following Resignation
- Leadership Change: Perrigo's Board has appointed Albert A. Manzone as Interim CEO following the resignation of Patrick Lockwood-Taylor due to personal conduct issues, highlighting the company's commitment to leadership standards.
- Strategic Continuity: As Interim CEO, Manzone pledges to maintain the company's strategic direction and momentum in value creation, reflecting confidence in the company's future despite leadership changes.
- Reaffirmed Performance Outlook: Perrigo has reaffirmed its 2026 financial outlook, projecting net sales growth between -5.5% and -1.5%, indicating stability in financial expectations amid leadership transitions.
- Extensive Leadership Experience: With over 30 years of global leadership experience across various industries, Manzone is expected to bring fresh perspectives and opportunities for value creation to Perrigo.
See More
Perrigo to Present at Oppenheimer Consumer Growth Conference
- Conference Schedule: Perrigo's President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are set to present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on June 9 at 10:30 AM EDT, highlighting the company's latest developments in consumer health.
- Webcast Access: Interested parties can access the conference webcast on Perrigo's official website, providing insights into the company's strategic direction and market performance, thereby enhancing investor confidence.
- Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience focused on delivering high-quality health and wellness solutions primarily to consumers in North America and Europe, ensuring accessibility and choice in the self-care market.
- Business Model: Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, enhancing its competitive position in the market.
See More
Perrigo Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Perrigo reported a Q1 non-GAAP EPS of $0.43, exceeding expectations by $0.12, indicating resilience in profitability despite revenue challenges.
- Significant Revenue Decline: The company’s revenue of $969 million fell 6.8% year-over-year, missing estimates by $71 million, reflecting intensified market competition and weak demand that could impact future market share.
- Core Sales Pressure: Core net sales were $842 million, down 8.3% year-over-year, with core organic net sales decreasing by 11.0%, highlighting the need for strategic adjustments in product lines and market approach to combat ongoing sales pressures.
- Unchanged Full-Year Outlook: Despite these challenges, Perrigo maintains its full-year 2026 outlook with expectations for improvement in the second half, demonstrating management's confidence in a potential market recovery.
See More
Perrigo Reports Q1 2026 Financial Results Amid Challenges
- Sales Decline: Perrigo's net sales for Q1 2026 were $969 million, a 7.2% decrease year-over-year, primarily due to weakened consumption in the U.S. and Europe, particularly affecting upper respiratory and pain relief products, indicating significant competitive pressure on the company.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, reflecting the dual pressures of rising production costs and declining sales volumes, which adversely impacted the company's overall profitability.
- Adjusted EPS Drop: The adjusted earnings per share stood at $0.43, a 28.3% decline year-over-year, highlighting challenges in profitability despite management's optimistic outlook for the second half of the year.
- Strategic Restructuring: Perrigo is implementing its
See More
Perrigo Appoints New CEO to Maintain 2026 Outlook
- Executive Change: Perrigo has appointed Albert A. Manzone as interim president and CEO effective immediately, following the resignation of former CEO Patrick Lockwood-Taylor, indicating a swift leadership adjustment to address market challenges.
- Leadership Experience: Manzone has served on Perrigo's Board since 2022 and brings over 30 years of global leadership experience, providing essential strategic guidance and stability during the company's transition period.
- Financial Outlook Maintained: Perrigo reaffirms its 2026 financial outlook, projecting adjusted EPS between $2.00 and $2.30, and core adjusted EPS between $2.25 and $2.55, demonstrating the company's confidence in its future performance.
- Cost Savings Target: The company also reiterated its sales growth targets while aiming for $60 million to $80 million in cost savings, which will enhance profitability and support long-term growth strategies.
See More
Albert A. Manzone Appointed Interim CEO Following Lockwood-Taylor's Resignation
- Leadership Transition: Perrigo Company has appointed Albert A. Manzone as Interim CEO effective immediately following Patrick Lockwood-Taylor's resignation due to personal conduct deemed inconsistent with the company's values, although this conduct did not affect business operations or financial reporting.
- Board Confidence: The Board expresses full confidence in Manzone's leadership capabilities, citing his 30 years of global experience and business transformation expertise as critical for maintaining strategic stability during this transition and continuing value creation.
- 2026 Outlook Reaffirmed: Perrigo reaffirmed its 2026 financial outlook, projecting net sales growth between -5.5% and -1.5%, and adjusted EPS of $2.00 to $2.30, indicating clarity in financial goals despite the leadership change.
- Manzone's Priorities: As Interim CEO, Manzone emphasizes continuity of the company's strategy and support for the leadership team to sustain momentum in value creation, demonstrating his commitment to the company's future growth.
See More
Perrigo Appoints Interim CEO Following Resignation
- Leadership Change: Perrigo's Board has appointed Albert A. Manzone as Interim CEO following the resignation of Patrick Lockwood-Taylor due to personal conduct issues, highlighting the company's commitment to leadership standards.
- Strategic Continuity: As Interim CEO, Manzone pledges to maintain the company's strategic direction and momentum in value creation, reflecting confidence in the company's future despite leadership changes.
- Reaffirmed Performance Outlook: Perrigo has reaffirmed its 2026 financial outlook, projecting net sales growth between -5.5% and -1.5%, indicating stability in financial expectations amid leadership transitions.
- Extensive Leadership Experience: With over 30 years of global leadership experience across various industries, Manzone is expected to bring fresh perspectives and opportunities for value creation to Perrigo.
See More
Perrigo to Present at Oppenheimer Consumer Growth Conference
- Conference Schedule: Perrigo's President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are set to present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on June 9 at 10:30 AM EDT, highlighting the company's latest developments in consumer health.
- Webcast Access: Interested parties can access the conference webcast on Perrigo's official website, providing insights into the company's strategic direction and market performance, thereby enhancing investor confidence.
- Company Background: Perrigo is a leading pure-play consumer health company with over a century of experience focused on delivering high-quality health and wellness solutions primarily to consumers in North America and Europe, ensuring accessibility and choice in the self-care market.
- Business Model: Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments in leading brands such as Opill®, Mederma®, and Compeed®, enhancing its competitive position in the market.
See More
Perrigo Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: Perrigo reported a Q1 non-GAAP EPS of $0.43, exceeding expectations by $0.12, indicating resilience in profitability despite revenue challenges.
- Significant Revenue Decline: The company’s revenue of $969 million fell 6.8% year-over-year, missing estimates by $71 million, reflecting intensified market competition and weak demand that could impact future market share.
- Core Sales Pressure: Core net sales were $842 million, down 8.3% year-over-year, with core organic net sales decreasing by 11.0%, highlighting the need for strategic adjustments in product lines and market approach to combat ongoing sales pressures.
- Unchanged Full-Year Outlook: Despite these challenges, Perrigo maintains its full-year 2026 outlook with expectations for improvement in the second half, demonstrating management's confidence in a potential market recovery.
See More
Perrigo Reports Q1 2026 Financial Results Amid Challenges
- Sales Decline: Perrigo's net sales for Q1 2026 were $969 million, a 7.2% decrease year-over-year, primarily due to weakened consumption in the U.S. and Europe, particularly affecting upper respiratory and pain relief products, indicating significant competitive pressure on the company.
- Margin Compression: The reported gross margin was 33.6%, down 400 basis points from the previous year, reflecting the dual pressures of rising production costs and declining sales volumes, which adversely impacted the company's overall profitability.
- Adjusted EPS Drop: The adjusted earnings per share stood at $0.43, a 28.3% decline year-over-year, highlighting challenges in profitability despite management's optimistic outlook for the second half of the year.
- Strategic Restructuring: Perrigo is implementing its
See More
